Guideline on when to start antiretroviral therapy and on pre-exposure prophylaxis for HIV (2015)



2015, 76 pages
ISBN 978 92 415 0956 5

This guideline makes available two key recommendations that were developed during the revision process in 2015. First, antiretroviral therapy (ART) should be initiated in everyone living with HIV at any CD4 cell count. Second, the use of daily oral pre-exposure prophylaxis is recommended as a choice for people at substantial risk of HIV infection as part of combination approaches to prevention. The first of these recommendations is based on evidence from clinical trials and observational studies released since 2013, showing that earlier use of ART results in better clinical outcomes for people living with HIV than delayed treatment. The second recommendation is based on clinical trial results confirming the efficacy of the antiretroviral drug tenofovir for use as pre-exposure prophylaxis to prevent people from acquiring HIV in a wide variety of settings and populations.